Anti-HSA single-domain antibodies and uses thereof for assessing renal function
Anti-HSA single-domain antibodies and their fusion proteins address the limitations of existing renal function diagnosis methods by providing a specific, stable, and cost-effective solution for HSA quantitation in urine, enabling early detection of renal dysfunction.
Patent Information
- Application Number
- PCT/CN2023/123865
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-30
- Filing Date
- 2023-10-10
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for diagnosing renal function, particularly through the measurement of Human Serum Albumin (HSA) in urine, are limited by the reliance on animal-derived antibodies, which are expensive and inefficient, and lack specificity and thermal stability, hindering early detection of renal dysfunction.
Development of anti-HSA single-domain antibodies and their fusion proteins, which can be used in lateral flow strips for specific binding and quantitation of HSA, enabling efficient assessment of renal function without animal-derived components, offering high specificity and thermal stability.
The anti-HSA single-domain antibodies provide a cost-effective, specific, and stable solution for diagnosing renal function by enabling accurate quantitation of HSA in urine samples, facilitating early detection of renal dysfunction and related health issues.
Smart Images

Figure CN2023123865_28112024_PF_FP_ABST
Abstract
Description
Anti-HSA single-domain antibodies and uses thereof for assessing renal functionTechnical Field
[0001] The field of this invention is biological technology. More specifically, antibodies and binding reagents are used in protein identification, quantitation, and purification.Background Art
[0002] Human serum albumin (HSA) is the most abundant protein in human plasma with concentration about 42 g / L, constituting more than half of the total protein content. HSA binds various molecules and ions (fatty acids, amino acids, metabolites, hormones, bilirubin, nutrients, drug molecules, metal ions, etc.) and is the principal contributor to the maintenance of colloid osmotic pressure. HSA consists of 585 amino acid residues, and its calculated molecular weight is 67 kDa.
[0003] Renal function is essential for homeostasis. Early diagnosis of renal dysfunction and initiation of appropriate therapy are vital to survival. The kidneys play important pleiotropic roles including removal of metabolic waste products and maintenance of water-electrolyte balance and blood pressure. Kidney contains up to a million functioning units called nephrons. A nephron consists of a filtering unit of tiny blood vessels called glomerulus attached to a tubule. When blood enters the glomerulus, it is filtered, and the remaining fluid then passes along the tubule. In the tubule, chemicals and water are either added to or removed from this filtered fluid according to the body's needs, and urine is the final excreted product.
[0004] The molecular weight cutoff for glomerular filtration is thought to be 30–50 kDa. Although abundant in blood, HSA exists only in very small amount in urine, due to its size above the cutoff. Therefore, the amount of HSA in urine is related to the efficiency of glomerular filtration and is a diagnostic marker for renal function. For diagnosis, HSA in urine may be measured in 24-hour urine collections. Normally, HSA in urine is below 30 mg per 24 hours. Microalbuminuria is when HSA is at 30-300 mg per 24 hours, and macroalbuminuria is when HSA is above 300 mg. Microalbuminuria and macroalbuminuria indicate that your kidneys aren’t functioning optimally and can be a sign of kidney disease, cardiovascular disease, and other health problems.
[0005] Lateral flow strip (dipstick) immunoassays are based on specific antibody-antigen binding and provide rapid and semi-quantitative measurement of proteins in complex biological samples. The lateral flow strip is comprised of a nitrocellulose membrane covered by a sample pad and binding pad on one end and an absorbing pad on the other end. For a colloidal gold-based strip, the antibody is colored with colloidal gold and flows through the nitrocellulose membrane, along with the sample to be analyzed. In a competition assay, the colored antibody binds its antigen that is fixed on the nitrocellulose membrane to form a colored band and the antigen in the sample, and the intensity of colored band negatively correlates with the amount of antigen in the sample. In a sandwich assay, the colored antibody binds its antigen in the sample, and the antibody-antigen complex binds another antibody that is fixed on the nitrocellulose membrane to form a colored band, and the intensity of colored band positively correlates with the amount of antigen in the sample.
[0006] Antibodies have been widely used in immunoassays, including the lateral flow strip immunoassays. However, both monoclonal and polyclonal antibodies rely on animals and animal cells during their discovery, development, and production. Therefore, antibodies are expensive. Single domain antibodies (also called nanobodies) are originated from unique heave-chain only antibodies in camelid animals and engineered to shorten to the single antigen binding domain. Single domain antibodies can be discovered, developed, and produced without using animals or animal cells. They are often seen as alternatives to conventional antibodies and show similarities in high and specific binding of their antigens but significant differences in other properties, such as thermal stability, tissue penetration, immunogenicity, and production costs.Summary of Invention
[0007] The object of the present disclosure is to provide two single domain antibodies that specifically bind HSA at two different epitopes. Their native forms, their fusion proteins, and their modified derivatives can be used in identification, quantitation, and purification of HSA, especially for assessment of renal function with lateral flow strips.
[0008] In the first aspect of the present disclosure, it provides the two single domain antibodies. Each of said single domain antibodies has three complementary determining regions CDR1, CDR2, and CDR3, located alternately with framework regions FR1, FR2, FR3, and FR4, as in a typical single domain antibody. Each of said single domain antibodies contains the CDR1, CDR2, CDR3 combination of the amino acid sequences defined by SEQ ID NOS: 1, 2, and 3; or SEQ ID NOS: 4, 5, and 6.
[0009] In one preferred embodiment, the CDR1, CDR2, CDR3 combination of sequences has sequences with identity of 80% or more, to one of said CDR1, CDR2, CDR3 combinations of sequences.
[0010] In the second aspect of the present disclosure, it provides the two single domain antibodies according to the first aspect of the present disclosure, and each of said single domain antibodies contains the amino acid sequence defined by SEQ ID NOS: 7, or 8.
[0011] In one preferred embodiment, the amino acid sequence has a sequence with identity of 80% or more, to said sequences.
[0012] In the third aspect of the present disclosure, it provides a fusion protein between one or more single domain antibodies according to the first, or the second aspect of the present disclosure, and one or more additional sequences of the fusion partner.
[0013] In one preferred embodiment, said additional sequence is selected from the group of short peptides, comprising signal peptide (such as,pelB as MKYLLPTAAAGLLLLAAQPAMA, OmpA as MKKTAIAIAVALAGFATVAQA, and DsbA as MKKIWLALAGLVLAFSASAAQ), affinity tag (such as, His tag as HHHHHH, and HA tag as YPYDVPDYA), and amino acid residues with chemically modifiable amino, carboxyl, or thiol groups (such as, Lys, Asp, Glu, and Cys).
[0014] In another preferred embodiment, said additional sequence is selected from the group of binding proteins, comprising single domain antibody, scFv, Fab, avidin, and streptavidin.
[0015] In another preferred embodiment, said additional sequence is selected from the group of fluorescent proteins, such as green fluorescent protein.
[0016] In another embodiment, said additional sequence is selected from the group of enzymes commonly used in detection, quantitation, and other purposes, comprising luciferase, alkaline phosphatase (AP), horseradish peroxidase (HRP), and sortase.
[0017] In another embodiment, said additional sequence is selected from the group of proteins commonly used in improvement of protein expression and refolding, comprising SUMO, maltose binding protein (MBP), and glutathione S-transferase (GST).
[0018] The fourth aspect of the present disclosure provides six fusion proteins according to the third aspect of the present disclosure, and each of said fusion proteins contains (1) His tag, (2) MBP, or (3) GST as the fusion partner. Their amino acid sequences are defined by translation of the nucleotide sequence as shown in either of SEQ ID NOS: 9-14.
[0019] The fifth aspect of the present disclosure provides the derivative modified by a modifier covalently or noncovalently from single domain antibodies according to the first, or the second aspect of the present disclosure, or from fusion proteins according to the third, or the fourth aspect of the present disclosure.
[0020] In one preferred embodiment, said modifiers are colored colloidal particles that comprises colloidal gold, colloidal silver, and colloidal carbon.
[0021] In another preferred embodiment, said modifiers are surface-coated beads with modifiable groups such as amino, carboxyl, thiol on the surface that comprises color or colorless beads, fluorescent beads, quantum dots, and magnetic beads.
[0022] In another preferred embodiment, said modifiers are chromatographic resins that comprises agarose, cellulose, dextran, and synthetic resins.
[0023] In another preferred embodiment, said modifier comprises luminogenic compounds, such as luminol, and acridinium esters.
[0024] In another preferred embodiment, said modifier comprises biotin, and biotin analogs and derivatives.
[0025] In another preferred embodiment, said modifier comprises fluorescent compounds, such as fluorescein, rhodamine, and their analogues.
[0026] In another embodiment, said modifier is selected from the group of enzymes, comprising luciferase, alkaline phosphatase, and horseradish peroxidase.
[0027] In another embodiment, said modifier comprises polymer membranes used in separation, filtration, and blotting, such as polyvinylidene fluoride (PVDF), nitrocellulose (NC), and nylon.
[0028] The sixth aspect of the present disclosure provides the lateral flow strip or dipstick, constructed by using the single domain antibodies according to the first, or the second aspect of the present disclosure, the fusion proteins according to the third, or the fourth aspect of the present disclosure, or the derivatives according to the fifth aspect of the present disclosure.
[0029] In one preferred embodiment, said lateral flow strip comprises sample pad, binding pad, developing pad, and absorbing pad.
[0030] In another preferred embodiment, said binding pad is glass fibers. One single domain antibody, its fusion protein, or its derivative is colored by noncovalently binding to colloidal gold and soaked on the binding pad.
[0031] In another preferred embodiment, said developing pad is a nitrocellulose membrane. Two test lines (T1 and T2) are on the developing pad: T1 with another single domain antibody, its fusion protein, or its derivative, fixed on the line, and T2 with antigen HSA fixed on the line.
[0032] In another preferred embodiment, said developing pad is a nitrocellulose membrane. Two lines (T as the test line, and C as the control line) are on the developing pad: T with antigen HSA fixed on the line, and C with another antigen or antibody as the control fixed on the line.
[0033] In another preferred embodiment, the lateral flow strip is put into a plastic enclosure as a cassette.
[0034] The seventh aspect of the present disclosure provides the use of the lateral flow strip according to the sixth aspect of the present disclosure for assessment and diagnosis of renal function and other physical and pathological conditions.
[0035] In one preferred embodiment, urine sample is collected and applied onto the said lateral flow strip at the sample pad. By comparing the relative color intensity of the T1 and T2 lines, or T and C lines, the amount of HSA in the urine sample is determined qualitatively or quantitatively.
[0036] The eighth aspect of the present disclosure provides the industrial and medical use of the single domain antibodies according to the first, the second aspect of the present disclosure, the fusion proteins according to the third, the fourth aspect of the present disclosure, or the derivatives according to the fifth aspect of the present disclosure.
[0037] In one preferred embodiment, our single domain antibody or its fusion protein is attached chemically to solid materials such as chromatographic resins, or magnetic beads, to construct affinity resins or affinity beads. With high affinity and specificity of the single domain antibodies of the present disclosure, antigen HSA or HSA-containing proteins in solution can be absorbed onto the solid materials and released back into solution after impurities are washed away, to achieve affinity protein purification.
[0038] In another preferred embodiment, an enzyme-linked immunosorbent assay (ELISA) can be constructed by coating a polystyrene plate with one single domain antibody or its fusion protein (antibody1), and by attaching horseradish peroxidase (HRP) to another single domain antibody or its fusion protein (antibody2). The HRP-labeled single domain antibody becomes attached to the polystyrene plate through antigen HSA in the sample solution by forming a complex of antibody1-antigen-antibody2. The activity of HRP attached to the plate in the assay will be determined quantitatively as the amount of antigen HSA in the sample. HSA is a biomarker for several physiological and pathological conditions, such as HSA in urine for renal function and HSA in feces for gastrointestinal bleeding. Our nanobodies, their fusion proteins, and their derivatives enable quantitation of HSA in biological samples, providing the essential data for making diagnostic decisions.
[0039] In another preferred embodiment, the single domain antibodies can be fused to other therapeutic proteins, such as shown in caplacizumab, to prolong the half-life of fusion proteins in human bodies, taking advantage of their binding to HSA in plasma.
[0040] These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and claims.Description of Drawings
[0041] Figure 1. The specific binding of HSA by 2p at different concentrations, and stability of the binding when measured at 0, 7 or 14 days.
[0042] Figure 2. the specific binding of HSA by 4p at different concentrations, and stability of the binding when measured at 0, 7 or 14 days.
[0043] Figure 3. The Binding of biotin-labeled 4p at different concentrations of HSA, when unlabeled 2p was at 0, 2, 20, or 200 μg / ml in solution.
[0044] Figure 4. Binding of biotin-labeled 4p at different concentrations of HSA, when unlabeled 4p was at 0, 2, 20, or 200 μg / ml in solution.
[0045] Figure 5. Binding of biotin-labeled 4p at different concentrations of HSA, when unlabeled HSA was at 0, 2, 20, or 200 μg / ml in solution.
[0046] Figure 6. Specificity of the lateral flow strip, when BSA was at 100, 200, or 500 mg / ml in the sample.
[0047] Figure 7. The change of color intensity at T1 and T2 lines, when HSA was at 0, 20, 40, 80, 160, or 320 mg / L in the sample.
[0048] Figure 8. The repeatability of color intensity of the T1 and T2 lines when samples contained HSA at 10, 12, 15, 24, 28, 32 mg / ml.
[0049] Figure 9. The thermal stability of the lateral flow strip, when incubated at 100°C for 0, 30, or 60 min.Detailed Description
[0050] The present invention is further described in combination with specific embodiments. These examples are only for illustrating the present invention and are not intended to limit the scope of the present invention.
[0051] The capacity and diversity of the screening phage libraries are keys to generate single domain antibodies with high affinity and high specificity. The libraries used in the present invention had the capacity reached 8x109pfu, and good diversity. Antigen used was HSA purchased from commercial sources. Solid phase screening method was used with polystyrene plates coated with HSA antigen, and many diverse single domain antibodies were displayed by M13 phages. In the screening, factors affecting the enrichment of phage particles include the purity of antigen, the concentration of antigen coated, type and concentration of blocking agents, type and concentration of buffers, number of input phages, times used for binding and eluting. In this case, 5% milk as the blocking agent or no blocking agent was used alternately. The strength of eluting conditions was increased gradually to improve the specificity in the screening. By optimization of screening conditions, single domain antibodies with high affinity and high specificity were obtained.
[0052] Example 1: Screening of a phage library
[0053] The steps included binding, washing, eluting, and amplifying, in the screening of phage library with HSA coated as the antigen. To reduce non-specific binding, 5% milk or no blocking was used alternately. In the 8 wells of the micro plate strip, 100 µl of HSA at 10 µg / ml was added to each well (1 µg / well). 37°C, 2 hrs. After removing the supernatant, the wells were washed 5 times with PBST. For blocking, 200 µl of 5% milk was added to each well, 37°C, 2 hrs. After removing blocking solution, the wells were washed 5 times with PBST. Then, 100 µl of phage library suspension (capacity 8x109, titer 1x109cfu / ml) was added to each well. Incubation at room temperature with shaking for 1 hr. After removing the supernatant, the wells were washed 5 times with PBST. For eluting, 100 µl of 0.2 M Gly-HCl (pH 2.2) was added to each well. After standing at room temperature for 10 min, all eluting solutions were collected into a 1.5-ml centrifuge tube. Tris-HCl (1 M, 120 µl, pH 9.0) was added to neutralize the collection, which was then mixed by vertexing. A sample (20 µl) was saved for titer determination, and the remaining mixture was used for the next screening cycle after amplification.
[0054] Example 2. Identification of positive clones 2p and 4p
[0055] Colonies were picked randomly from the titer plate and phages were released from each of the colonies. ELISA method was used to identify the positive clones. In the 8 wells of the micro plate strip, 100 µl of HSA at 10 µg / ml was added to each well (1 µg / well). 37°C, 2 hrs. After removing the supernatant, the wells were washed 5 times with PBST. For blocking, 200 µl of 5% milk was added to each well, 37°C, 2 hrs. After removing the blocking solution, the wells were washed 5 times with PBST. Then, 100 µl of amplified monoclonal phage suspension was added to each well. The plate was incubated at room temperature with shaking for 1 hr. After removing the supernatant, the wells were washed 5 times with PBST. Then, 100 µl of rabbit anti-HA antibody was added to each well. The plate was incubated at room temperature with shaking for 45 min. The wells were washed with PBST 5 times. For determination, 100 µl of TMB reagent was added to each well. When the color intensity was adequate, 100 µl of 1 M HCl as the stopping solution was added to each well, and OD450 values were read immediately. Positive clones with high OD values were sent for sequencing, to obtain amino acid sequences. Two positive clones were identified with their sequences shown in SEQ ID NO: 7 and 8 and named as 2p and 4p.
[0056] Example 3. Construction of the single domain antibodies 2p and 4p fused to Hig tag
[0057] Several commercially available plasmids (such as the pET series, pET14b, pET-15b, pET-16b, pET-19b, pET-20b, pET-21a-d, pET-22b, pET-23a-d, etc.) can be used to introduce the His tag. To clone into pET23a, the single domain antibody sequence shown in SEQ ID NO: 7 or 8 was translated into a nucleotide sequence with NdeI and XhoI sites at the ends, and the gene fragment was ligated into the pET23a plasmid cut with the same restriction enzymes. The His tag located at the C-terminus enabled purification of the recombinant protein with nickel affinity column and identification by ELISA. The nucleotide sequences coding the fusion proteins are shown in SEQ ID NO: 9 or 10.
[0058] Example 4. Construction of the single domain antibodies 2p and 4p fused to MBP
[0059] Several commercially available plasmids (such as pMAL-p5E, pMAL-p5G, pMAL-c4X, pMAL-c5E, pMAL-c5X, etc.) can be used to fuse with MBP. To clone into pMAL-c5E, the single domain antibody sequence shown in SEQ ID NO: 7 or 8 was translated into a nucleotide sequence with NdeI and EcoRI at the ends, and the gene fragment was ligated into the pMAL-c5E plasmid cut with the same restriction enzymes. The nucleotide sequences coding the fusion proteins are shown in SEQ ID NO: 11 or 12.
[0060] Example 5. Construction of the single domain antibodies 2p and 4p fused to GST
[0061] Several commercially available plasmids (such as pGEX-2TK, pGEX-4T1, pGEX-4T2, pGEX-4T3, pGEX-5X1, pGEX-5X2, pGEX-5X3, pGEX-6P1, pGEX-6P2, pGEX-6P3, etc.) can be used to fuse with GST. To clone into pGEX4T1, the single domain antibody sequence shown in SEQ ID NO: 7 or 8 was translated into the nucleotide sequence with BamHI and XhoI at the ends, and the gene fragment was ligated into the pGEX4T1 plasmid cut with the same restriction enzymes. The nucleotide sequences coding the fusion proteins are shown in SEQ ID NO: 13 or 14.
[0062] Example 6: Expression and purification of 2p and 4p proteins in E. coli.
[0063] The plasmid pET23a (1 μl) with the gene coding single domain antibody with fusion partner (SEQ ID NO: 9 or 10), His tag in this case, was added to 50 µl of BL21(DE3) competent cells. After on ice for 30 min, the mixture was transferred to 42°C water bath for heat-shock for 60 sec. After on ice for 5 min, 450 µl of SOC medium was added. After mixing, the mixture was incubated at 37°C with shaking at 200 rpm for 1 hr. The mixture (200 μl) was applied to a LB plate with Amp, and after the liquid was dried, the plate was placed upside down and incubated at 37°C overnight. The next day, a single colony was picked and inoculated in 5 ml LB with Amp. After incubation at 37°C, 200 rpm, 8 hours, the culture was transferred into 330 ml TB broth with phosphate buffer and Amp. Incubation overnight at 30°C, 200 rpm. After centrifugation, the cell pellets were resuspended with phosphate buffer (20 mM, pH 7.4). The cells were broken with sonication (use 75% of the 150W power, that is 112.5W, 5 sec on, 20 sec off). After centrifugation for 20 min (4°C, 20,000 rpm), supernatants and precipitates were collected separately, and the supernatants were kept at -20°C. The precipitates were used to obtain proteins with high concentration and high purity. The precipitates were resuspended in 10 ml 2 M urea, more 2 M urea was added to 40 ml. Centrifugation for 10 min (4°C, 8,000 rpm). The precipitates were resuspended in 10 ml 8 M urea, more 8 M urea was added to 35 ml, and the mixture was left at room temperature for 1 hour with shaking at 80 rpm. Centrifugation for 20 min (4°C, 10,000 rpm). The supernatants with denatured proteins were collected. To reduce the urea content gradually, 15 ml of the supernatant (with 8 M urea) was added to 15 ml 1x PBS, to low the urea concentration from 8 M to 4 M. The mixture was dialyzed against 600 ml 2 M urea for 1 hour (4°C, in refrigerator). Part of the dialysis solution (200 ml) outside of the bag was removed, 1 M urea (200 ml) was added, and dialysis continued overnight. On the next day, another 200 ml was removed, 200 ml PBS was added, and the dialysis was continued for another hour. After the dialysis, the protein solution was centrifuged for 25 min (4°C, 10,000 rpm). Supernatants containing renatured proteins were collected. PAGE gel showed that the single domain nanobodies with C-his-tag had molecular weight between 15-20 kDa, consistent with the calculated molecular weights. No apparent impurities shown as bands on the gel, indicating good purity.
[0064] Example 7: Determination of affinity of 2p and 4p proteins and their thermal stability
[0065] 2p and 4p protein solutions were diluted with phosphate buffer (20 mM, pH 7.4) to the concentration at 1 mg / ml, and the centration was determined by Coomassie Blue method. Three samples were prepared for affinity determination: without 37°C incubation (unincubated), after incubation at 37°C for 7 days, and after incubation at 37°C for 14 days. In the 8 wells of a micro plate strip, 100 μl of HSA at 20 μg / ml was added, then incubation lasted for 2 hours at 37°C. After removing the solution, the wells were washed 5 times with PBST. 200 μl of 5% milk was added, then incubation lasted for 30 min at 37°C. After removing the solution, the wells were washed 5 times with PBST. The 2p or 4p protein was diluted as a 3-fold series with the first concentration at 20 μg / ml. The antibody protein solution (100 μl) at 8 different concentrations was added to each of the wells. Incubation lasted for 1 hour at room temperature. After removing the solution, the wells were washed 5 times with PBST. A tag-specific antibody (100 μl) was added to each well, and incubation lasted for 1 hour at room temperature. After removing the solution, the wells were washed 5 times with PBST. An HRP-labeled secondary antibody (100 μl, 1:5000 dilution) was added to each well, and incubation lasted for 1 hour at room temperature. After removing the solution, the wells were washed 5 times with PBST. TMB substrate solution (100 μl) was added to each well, and after about 5-10 min, when the color was at an appropriate darkness, stop solution (1 M HCl, 100 μl) was added. OD values at 450 nm were read on a microplate reader, and results were analyzed by using Excel. The affinity results from ELISA are shown in Figure 1 and Figure 2, and their EC50 values were calculated as 222 and 172 ng / ml, respectively, for the 2p and 4p unincubated samples. The curves of unincubated, incubated for 7 days, and incubated for 14 days did not show significant shifts, indicating the high stability of the 2p and 4p proteins.
[0066] Example 8: Biotination of 4p protein
[0067] The purified 4p protein was diluted with phosphate buffer (20 mM, pH 7.4) to the concentration at 1 mg / ml. NHS-Biotin was prepared as 10 mM DMSO solution, and it was added to the 4p protein solution in an 8:1 molar ratio. The mixture was shaked at room temperature at 50 rpm for one hour. To remove salts, Sephadex G-25 resin column was used. The column was first equilibrated with phosphate buffer (20 mM, pH 7.4), and then the biotinated protein was loaded onto the column and eluted, with Coomassie Blue R-250 used to monitor the eluents. Protein-containing fractions were collected, before the column was washed and preserved by filling 20% ethanol. The collected protein fractions were combined and named as 4p-biotin solution.
[0068] Example 9: Competitive binding between 2p and 4p proteins to HSA
[0069] In the 8 wells of a micro plate strip, 100 μl of HSA at 20 μg / ml was added, then incubation lasted for 2 hours at 37°C. After removing the solution, the wells were washed 5 times with PBST. 200 μl of 5% milk was added, then incubation lasted for 30 min at 37°C. After removing the solution, the wells were washed 5 times with PBST. Prepared 12 8-well strips, and 8 wells in each strip were filled with unlabeled 2p, unlabeled 4p, or unlabeled HSA at final concentrations of 0, 2, 20, or 200 μg / ml. Serially diluted 4p-biotin solutions (100 μl, initial concentration at 1 μg / ml, 3-fold dilutions, 8 concentrations) were added to wells of the 12 8-well strips. Incubation with shaking at room temperature at 80 rpm for 45 minutes. After removing the solution, the wells were washed 5 times with PBST. SA-HRP (100 μl) was added, and the mixture was incubated at room temperature with shaking at 80 rpm for 45 minutes. After removing the solution, the wells were washed 5 times with PBST. TMB substrate solution (100 μl) was added to each well, and after about 5-10 min, when the color was at an appropriate darkness, stop solution (1 M HCl, 100 μl) was added. OD values at 450 nm were read on a microplate reader and results were analyzed by using Excel. The ELISA results are shown in Figures 3, Figures 4 and Figure 5, and 4p-biotin showed good affinity with a calculated EC50 value at 18 ng / ml. After adding unlabeled 2p, the curves of 4p-biotin binding showed no significant move (Figure 3), indicating that 2p and 4p proteins bind at different epitopes on antigen HSA. In the experiments performed at the same time, adding unlabeled 4p protein significantly affected the binding of 4p-biotin, as big shifts of the binding curves (Figure 4), indicating that 4p-biotin and unlabeled 4p competed for the same epitope on HSA. In similar experiments by adding extra antigen HSA, the extra HSA affected the binding of 4p-biotin to precoated HSA on the plate, as big shifts of the binding curves (Figure 5), indicating that 4p-biotin bind HSA specifically.
[0070] Example 10: Modification of 2p and 4p proteins by colored beads and fluorescent beads
[0071] We carried out labelling of 2p and 4p proteins with colored beads and fluorescent beads. MES buffer (100 mM, pH 6.0), EDC, and SulfoNHS solution (20 mg / ml) were prepared. Blue beads (25 μl) and MES buffer (975 μl) were mixed, and green fluorescent beads (25 μl) and MES buffer (975 μl) were mixed. To each of the 1-ml mixture, 0.5 mg 2p or 4p protein, 5 μl SulfoNHS solution, and 10 μl EDC solution were added,. Incubation at room temperature in dark with shaking at 80 rpm lasted for 20 minutes, and then the mixture was centrifuged at 17,000 g for 20 minutes. After removing supernatant, the pellets were washed with and resuspended in phosphate buffer (20 mM, pH 7.4). The suspension was centrifuged, and the pellets were resuspended in 1 ml PBS, as the labeled beads. The suspension of the labeled blue beads showed blue color, and the suspension of the labeled green fluorescent beads showed green color and glowed green fluorescence when a green laser pointer was pointed.
[0072] Example 11: Solutions used for making lateral flow strips
[0073] 10 mM PBS buffer: Na2HPO41.44 g, KH2PO40.24 g, K2HPO41.8 g, KCl 0.2 g, NaCl 7.9 g. Add water to 1 L. Solubilize by stirring. Adjusted pH to 7.2-7.4.
[0074] 50 mM Tris buffer: Tris base, 6.06 g. Add water to 1 L. Adjusted pH to 8.0±0.1 by adding HCl (about 2.1 ml conc. HCl).
[0075] Blocking solution (10% BSA): BSA 5 g. Add water to 50 ml. Solubilized by stirring.
[0076] Diluting solution: Isopropanol (200 µl) was added to 10 ml of 10 mM PBS solution.
[0077] Resolubilizing solution for colloidal gold-labelled antibody: BSA, 1g; trehalose, 8 g. Add 100 ml of 50 mM Tris buffer. Solubilized by stirring. Added 100 µl of Tween-20. Mix by stirring.
[0078] Example 12: Modification of 4p protein by colloidal gold
[0079] The pH of colloidal gold solution was adjusted by adding K2CO3(9 µl of 0.2 M K2CO3per 1 ml colloidal gold solution). The solution was stirred for 5-10 min and 4p protein (10 µg of 4p per 1 ml colloidal gold solution) was added slowly to the colloidal gold solution. The solution was stirred at low speed for 30 min. Blocking solution was added to its final concentration at 10% (weight ratio) and the solution was stirred for 20 min. The solution was centrifuged at 12,000 rpm for 30 min after standing for 30 min. Supernatant was removed, and the colloidal gold-labelled 4p protein pellets were resolubilized with 70 µl of resolubilizing solution.
[0080] Example 13: Preparation of binding pad and developing pad
[0081] The resolubilized labelled 4p protein was sprayed to the binding pad. The binding pad was dried before use. HSA was diluted with the diluting solution to 3.5 mg / ml, and then sprayed to the developing pad (nitrocellulose) at the position of T1 at a spray speed of 0.8 µl / cm. 2p protein was diluted with the diluting solution to 0.7 mg / ml, and then sprayed to the developing pad at the position of T2 at a spray speed of 1.8 µl / cm. The developing pad was dried before use.
[0082] Example 14: Assembly of the lateral flow strip
[0083] On the PVC backing (80 mm x 300 mm x 0.42 mm) with adhesives on one side, the sample pad, binding pad, developing pad, and absorbing pad were placed in order with 2 mm overlaps. The backing was cut to strips of 80 mm x 4 mm. In the case for making cassettes, a plastic cassette of the size of 100 mm x 16 mm x 5 mm was used, to enclose the strip.
[0084] Example 15: Use of the lateral flow strip
[0085] Samples (freshly collected urine, or HSA in artificial urine) were prepared for testing. The lateral flow strip was inserted vertically for about 5 mm depth into the urine sample at the sampling end (the end with sample pad) for 10 sec and placed horizontally afterwards. The relative color intensities between T1 and T2 lines were recorded. T1>T2, negative. T1=T2, threshold value. T1<T2, positive.
[0086] Example 16: Determination of the specificity of the lateral flow strip
[0087] Samples using bovine serum albumin (BSA) at 100, 200, 500 mg / L were prepared in artificial urine and tested with the lateral flow strips. As shown in Figure 6, at these three testing BSA concentrations, T1 showed clear band, and T2 showed no band, indicating that the strips were specific for HSA and distinguished between HSA and BSA.
[0088] Example 17: Determination of the range and hook effect of the lateral flow strip
[0089] Samples using HSA at 0, 20, 40, 80, 160 and 320 mg / L were prepared in artificial urine and tested with the lateral flow strips. As shown in Figure 7, at these testing HSA concentrations, varied color intensities of T1 and T2 bands were observed. At 80 mg / L, T2 band was weakened, likely due to hook effect. At 320 mg / L, T2 band was even weaker, due to hook effect, but T2 band was still darker than T1, giving a positive and correct result. The results indicate that correct results were obtained in the testing range of 0-320 mg / L.
[0090] Example 18: Determination of the repeatability and limits
[0091] Samples using HSA at 10, 12, 15, 24, 28 and 32 mg / L were prepared in artificial urine. The lateral flow strips (30 strips) were tested in 6 groups (5 strips per group) in these HSA concentrations. As shown in Figure 8, at 12 mg / L, all tested showed negative (100% correct); at 28 mg / L, all tested showed positive (100% correct). The results indicate that the strips showed good repeatability and detection limit was at 28 mg / L.
[0092] Example 19: Determination of the thermal stability of the lateral flow strip
[0093] Samples using HSA at 8, 12, 16, 20, 24, 28 and 32 mg / L were prepared in artificial urine. The lateral flow strips (210 strips) were treated in 3 groups (70 strips per group) at 100°C water bath for 0, 30 and 60 min. Each of three treated strip groups were tested as 7 subgroups (10 strips per subgroup) at the seven HSA concentrations with score of 2 for negative, 1 for at threshold value, and 0 for positive. The scores were totaled for each subgroup. As shown in Figure 9, The scores correlated with HSA concentrations and the strips showed good thermal stability.
[0094] Although the present invention has been described in considerable details with reference to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained therein.
Claims
1.Anti-HSA single-domain antibodies, which have complementary determining regions (CDR1, CDR2, and CDR3) with amino acid sequences defined by SEQ ID NO: 1-3 or by SEQ ID NO: 4-6.2.The anti-HSA single-domain antibody of claim 1, which has the amino acid sequence defined by SEQ ID NO: 7 or 8.3.A fusion protein, which is fused between one or more single-domain antibodies of claim 1 or 2 and one or more peptides or proteins as the fusion partner, and the fusion partner includes His tag, HA tag, alkaline phosphatase, maltose binding protein, glutathione S-transferase, protein toxin, and antibody Fc fragment.4.The fusion protein of claim 3, which has its amino acid sequence by translation of the nucleotide sequence defined by either of SEQ ID NO: 9-14.5.A derivative, which is formed by modifications of the single-domain antibody of claim 1 or 2, or the fusion protein of claim 3 or 4, Non-covalently with modifiers including colloidal gold, colloidal silver, and colloidal carbon, orCovalently with modifiers including colored beads, fluorescent beads, magnetic beads, chromatographic resins, filtration membranes, or small molecules that include biotin and its derivatives, dyes, and fluorescent molecules.6.A lateral flow strip, with sample pad, binding pad, developing pad, and absorbing pad, which contains the single-domain antibody of claim 1 or 2, the fusion protein of claims 3 or 4, or the derivative of claim 5.7.The use of the lateral flow strip of claim 6 for measuring HSA in urine in assessment and diagnosis of renal function and other physical and pathological conditions.8.The use of the single-domain antibody of claim 1 or 2, the fusion protein of claims 3 or 4, or the derivative of claim 5, in purification and characterization of HSA-containing proteins, diagnosis by measuring HSA qualitatively and quantitatively, and therapy involving binding to HSA.
Citation Information
Patent Citations
Anti-human serum albumin single-chain antibody and method for connecting polypeptide drugs to carbon end thereof
CN102827277A
Anti-human serum albumin single-chain antibody and method for connecting polypeptide medicine with nitrogen terminal of antibody
CN102875675A
Single domain antibody for recognizing human serum albumin
CN107674122A
Anti-human serum albumin single domain antibody, and preparation method and application thereof
CN111138536A
Novel anti-human serum albumin antibody fragment, preparation method and application
CN111138537A
